---
title: "Jenkem Technology Co., Ltd. (688356.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688356.SH.md"
symbol: "688356.SH"
name: "Jenkem Technology Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T03:27:51.582Z"
locales:
  - [en](https://longbridge.com/en/quote/688356.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688356.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688356.SH.md)
---

# Jenkem Technology Co., Ltd. (688356.SH)

## Company Overview

Jenkem Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol derivative (PEG) products in China and internationally. The company offers high molecular weight polyethylene glycol derivatives comprising branched, methoxylated, bifunctionalized, heterofunctionalized disubstituted, multi-arm, multi-arm heterofunctional disubstituted, amino-polyglycolic, N-terminated polyethylene glycol-modified, and thiol-modified polyethylene glycol PEG products; monodisperse PEG products consisting of methoxy monodisperse PEG derivatives, and monodisperse PEG derivatives with the same functional and heterofunctional groups; click chemistry; lipid nanoparticles delivery system accessories; PEG linkers, such as ADC and PROTAC linkers; PEG medical devices, which include multi-arm PEG derivatives; polyethylene glycol standards; block copolymers; PEG standards; long-acting polypeptide fatty acid side chains, including semaglutide, tirzepatide/icodec, and somapacitan intermediates; and Silkrose injectable cross-linked sodium hyaluronate gel, a passive implantable device used to correct moderate to severe nasolabial folds through subcutaneous injection. It also provides technical services comprising development of synthetic methods, quality research and IND application, analytical method development, and polyethylene glycolization technology services. Jenkem Technology Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.jenkem.com](https://www.jenkem.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.29)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 47 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 41.85% |  |
| Net Profit YoY | 164.92% |  |
| P/B Ratio | 3.80 |  |
| Dividend Ratio | 0.18% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5080704924.49 |  |
| Revenue | 327946390.27 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.52% | C |
| Profit Margin | 22.01% | A |
| Gross Margin | 70.22% | A |
| Revenue YoY | 41.85% | A |
| Net Profit YoY | 164.92% | A |
| Total Assets YoY | 3.35% | C |
| Net Assets YoY | 4.72% | C |
| Cash Flow Margin | 187.01% | B |
| OCF YoY | 41.85% | A |
| Turnover | 0.23 | D |
| Gearing Ratio | 5.74% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jenkem Technology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "41.85%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "164.92%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.80",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.18%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5080704924.49",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "327946390.27",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.52%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "22.01%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "70.22%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "41.85%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "164.92%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.35%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.72%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "187.01%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "41.85%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.23",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "5.74%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 70.40 | 121/215 | 219.78 | 160.78 | 141.16 |
| PB | 3.80 | 161/215 | 4.71 | 4.41 | 3.83 |
| PS (TTM) | 15.49 | 203/215 | 25.10 | 23.33 | 19.62 |
| Dividend Yield | 0.18% | 149/215 | 0.18% | 0.16% | 0.15% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-07T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 82.01 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688356.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688356.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688356.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688356.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**